<DOC>
	<DOCNO>NCT01422382</DOCNO>
	<brief_summary>This Phase 4 , single-center , open-label , fixed-sequence , multiple-dose , 2-way drug-drug interaction study .</brief_summary>
	<brief_title>Drug-Drug Interaction Cardizem LA ( Diltiazem Hydrochloride ) Pitavastatin</brief_title>
	<detailed_description>Each subject qualify entry study 30 day prior admission clinical unit . Subjects check clinical unit Day -1 baseline assessment . During treatment period , subject receive once-daily dose pitavastatin 4 mg Days 1 5 Days 11 15 once-daily dose diltiazem 240 mg Days 6 15 . Subjects fast overnight least 8 hour dose remain fasted 4 hour dose morning Days 5 , 10 , 15 .</detailed_description>
	<mesh_term>Pitavastatin</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<criteria>Healthy adult male female volunteer age 18 45 year , inclusive . Subject body mass index 18 30 kg/m2 , inclusive . Subject normal hematology , serum chemistry , urinalysis test result . Subject able willing abstain alcohol , grapefruitcontaining food beverage , caffeine , caffeinecontaining product , St John 's wort , herbal supplement 4 day Day 1 completion study . Subject nonsmoker quit smoke least 6 month first dose study drug study completion . Subject surgery gastrointestinal tract likely affect drug absorption , distribution , metabolism , excretion . Subject previous allergy intolerance treatment pitavastatin , diltiazem , drug class . Subject history drug alcohol abuse . Subject clinically significant illness within 4 week first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>